|
The first ever
peptide-powered
neuromodulator fda
approved for frown lines
|
|
Dear Dr. XX:
|
|
After decades of research, the first ever peptide-powered neuromodulator FDA approved for frown lines has arrived.
|
|
Meet DAXXIFY® (daxibotulinumtoxinA-lanm) – winner of Time’s Best Inventions of 2023, and a winner of Cosmopolitan’s 2024 Holy Grail Beauty Awards. DAXXIFY® provides patients with a unique range of benefits:
|
|
•
|
SEE RESULTS FAST: Results seen as early as the next day for some, and typically within 2 days.1‡
|
|
•
|
WATCH RESULTS LAST: Long lasting and keeps frown lines smoother with the convenience of as few as 2 treatments a year.* Results slowly soften over a prolonged period of time.2,4§
|
|
•
|
THE DAXXIFY® LOOK: Improvement in the appearance of skin texture,3† smoothing even the deepest lines.2,5,6
|
|
|
Not all neuromodulators are created equally. That’s the DAXXIFY® Difference – all of these benefits are made possible by the formulation powered by Peptide Exchange Technology.
|
|
Ready to learn more about DAXXIFY®? Let’s talk and discuss how DAXXIFY® can provide you a new way to treat your patient’s frown lines.
|
|
Become a Daxxify Account
|
|
INDICATION
DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
|
WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than glabellar lines.
|
|
IMPORTANT SAFETY INFORMATION
Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
|
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
|
Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).
|
Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.
|
Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.
|
|
Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.
|
|
REFERENCES
|
| 1. |
Data on File. D220801001. Newark, CA: Revance Therapeutics, Inc, 2021. |
| 2. |
Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845. |
| 3. |
Data on File. D231201010. Newark, CA: Revance Therapeutics, Inc, 2023. |
| 4. |
Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58. |
| 5. |
Data on File. Gross. American Academy of Dermatology. Newark, CA: Revance Therapeutics, Inc, 2021. |
| 6. |
Brown J, Stephenson J, Kooken K, Sparrow J. Impact of DaxibotulinumtoxinA for Injection on skin smoothness following treatment of glabellar lines. Poster presented at: Derm2023 NP/PA CME Conference; August 3-6, 2023; Las Vegas, NV. |
| 7. |
DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc, 2022. |
| 8. |
Botox® Cosmetic. Prescribing Information. Allergan Inc; 2020. |
| 9. |
Xeomin®. Prescribing Information. Merz Pharmaceuticals GmbH; 2021. |
| 10. |
Dysport®. Prescribing Information. Ipsen Biopharm Ltd; 2023. |
| 11. |
Jeuveau®. Prescribing Information. Evolus, Inc; 2020. |
|
|
|
